Selonterra Achieves New Patent Milestone in Alzheimer's Research
Selonterra, Inc., a pioneering biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, has reached a remarkable milestone with the granting of a United States patent by the U.S. Patent and Trademark Office. This patent, numbered 12,385,093, focuses on groundbreaking discoveries related to Alzheimer's disease and the mechanisms behind it.
Understanding the Impact of APOE4 in Alzheimer's Disease
One of the most significant themes in Alzheimer’s disease research is the genetic factors that influence its onset and progression. Among these, the APOE4 allele stands out as the leading genetic risk factor associated with late-onset Alzheimer's disease. Selonterra's research centers on how a single nucleotide change in the APOE4 gene is crucial in regulating nearby genes’ expressions, yielding novel targets for therapeutic intervention.
By concentrating on the genetic aspects of Alzheimer’s, Selonterra is paving the way for new treatments that exploit the mechanisms of the APOE4 allele. The research indicates that targeting these APOE4-motif mediated genes could lead to the development of small molecule drugs specifically designed to combat Alzheimer's disease.
Leadership and Commitment to Innovation
Roman Urfer, PhD, the Founder and CEO of Selonterra, emphasized the importance of intellectual property in their research journey. He stated, “We relentlessly pursue intellectual property coverage along the entire development path from our early discoveries, through novel targets to small molecule composition of matter patents.” This strategic approach underlines Selonterra's ambition to ensure that their innovations are well protected as they advance through the stages of drug development.
Innovative Strength Behind the Patent
The issuance of this patent reflects Selonterra’s dedication to exploring the nuances of genetic factors in Alzheimer’s disease. Anne Urfer-Buchwalder, PhD, the Founder and President, remarked on the importance of their new findings, stating that this patent demonstrates the innovative strength of their research team. “These discoveries enable us to exploit the well-established APOE4 root cause of AD from a previously unappreciated angle,” she said. This innovative thinking is crucial for breaking new ground in treating neurodegenerative diseases.
About Selonterra, Inc.
Selonterra, Inc. is at the forefront of biological research in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The company employs a multidisciplinary approach that includes human genetics, detailed molecular pathway analysis, and intricate gene regulatory networks to pinpoint proprietary mechanisms that cause disease. They are focused on leveraging these insights to identify effective therapeutic targets.
Selonterra’s teams consist of seasoned scientists and industry executives who bring decades of combined experience in biotechnology and pharmaceutical sectors. They work alongside a global network of collaborators to foster advancements in medical treatments for debilitating conditions.
Investor and Media Contact Information
For inquiries from investors and media, Selonterra can be reached at:
T: (+1) 650 206 7025
E: Contact Us
Frequently Asked Questions
What significant milestone has Selonterra recently achieved?
Selonterra has been granted a key patent by the U.S. Patent and Trademark Office for its groundbreaking discoveries related to Alzheimer's disease and the APOE4 genetic marker.
How does the APOE4 genotype influence Alzheimer’s disease?
The APOE4 genotype is recognized as a major genetic risk factor for late-onset Alzheimer's, and Selonterra's research focuses on how it regulates nearby gene expressions relevant to the disease.
What differentiates Selonterra’s approach to Alzheimer's treatment?
Selonterra integrates human genetics and molecular analysis to discover novel therapeutic targets, particularly those associated with the APOE4 genotype.
Who are the founders of Selonterra, Inc.?
Selonterra was founded by Roman Urfer, PhD, and Anne Urfer-Buchwalder, PhD, both of whom bring extensive experience in biotechnology and research.
How can investors or the media contact Selonterra?
Interested parties can reach Selonterra by phone at (+1) 650 206 7025 or via email for further inquiries.
